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Abstract
Introduction. Atrial fibrillation (AF) is constantly associated with a complex of various factors that create a diversity of 
pathophysiological variants due to phenomenon of atrial remodelling. The aim of the study was to investigate clinical 
associations with plasma homocysteine (Hcy) and glycine (Gly) levels in patients with paroxysmal and persistent AF.
Materials and methods. The study included 94 patients with ischaemic heart disease and/or hypertension without 
significant structural myocardial damage — 48 subjects with paroxysmal AF (group 1) and 27 subjects with persistent 
AF (group 2). Control group consisted of 19 patients without history of AF. Echocardiography was performed to assess 
left atrium (LA) size and function. Plasma levels of Hcy and Gly were measured.
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Results. Patients with AF had significantly increased total plasma Hcy level. In group 2 there was a significant correlation 
between Hcy plasma level and LA-size. The Gly level > 349 μmol/L was found to be associated with a greater AF duration 
and was significantly more often in patients with AF existing for more than four years. Patients with Gly plasma level 
> 309 μmol/L and total Hcy plasma > 11.02 μmol/L showed significantly increased frequency of AF. Patients without 
AF showed Hcy plasma level < 11 μmol/L significantly more frequently (0% vs 29%) (р = 0.005).
Conclusion. There is an association between Hcy and Gly levels, atrial remodelling and the clinical course in patients 
with AF. It can be assumed that in a higher level of Hcy, increased Gly level may serve as a predictor of more pronounced 
structural and functional changes in the atria, but in such case it acts as a protective mechanism.
Key words: atrial fibrillation, homocysteine, glycine, fibrosis, left atrium, echocardiography, structural and functional 
remodelling
(Folia Cardiologica 2015; 10, 5: 323–329)
rious matrix metalloproteinases (MMP) may also influence 
the collagen extracellular matrix disintegration [5]. Further-
more, it was shown that homocysteine (Hcy) may regulate 
MMP-2 and 9 activity [6], which can lead to structural and 
electrical remodelling.
The aim of our study was to search for clinical asso-
ciations with homocysteine and Gly levels in patients with 
paroxysmal and persistent AF.
Materials and methods
Study population
Seventy-five patients admitted due to AF to the Arhythmo-
logy Department of the Grodno Regional Clinical Cardiology 
Centre (Belarus) have been observed.
These patients included 48 subjects with paroxysmal AF 
(group 1) and 27 subjects with persistent AF (group 2), wit-
hout significant structural myocardial damage. Persistent 
AF was defined as AF which is sustained beyond seven days, 
or lasting less than seven days but necessitating pharmaco-
logical or electrical cardioversion. The study control group 
included 19 patients without history of AF. All participants 
had background history of ischaemic heart disease (IHD) 
and/or hypertension. Patients with thyroid dysfunction, 
acute stroke, acute myocardial infarction, acute myocar-
ditis, known chronic heart failure (NYHA ≥ 2), diabetes, 
severe chronic diseases (e.g., severe renal or liver failure) 
or pregnancy were excluded from the study. Patients with 
diseases that lead to the Hcy metabolism disturbance and 
elevated levels of total plasma Hcy (B12-deficiency anaemia, 
cancer and leukaemia, renal failure, systemic lupus erythe-
matosus, rheumatoid arthritis) were also excluded, as well 
as patients taking vitamins B6, B12, folic acid and glycine 
drugs for less than 1 month prior to the study.
Routine laboratory and physical examinations were 
performed to eliminate cardiovascular diseases. All pa-
tients underwent instrumental and laboratory study after 
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhyth-
mia, the incidence of which increases regularly with age [1].
Etiological and pathophysiological aspects of AF are com-
plex and not fully understood. Currently, AF is considered as 
a result of complex various interconnected factors, such as 
electrophysiological, molecular, biological, genetic changes, 
the spectrum of which varies in each individual patient and 
creates a diversity of pathophysiological variants [2].
Two main theories of the AF pathogenesis — ectopic 
activity and focal “re-entry” mechanism, which require 
the presence of triggers and supporting substrate — has 
already been known, but even in their absence AF can 
exist. This occurs as a result of structural and electrical 
remodelling of the atria, which are characterized by the 
dilation and reduction of the effective refractory period. 
In addition, AF enhances the extracellular matrix proteins’ 
expression and activation of atrial fibrosis [3].
Atrial conduction slowing result in electrical insulation 
of cardiomyocytes. Changes in the extracellular matrix are 
shown to be increase in the atria and to accumulate colla-
gen in it, which leads to the development of fibrosis. These 
processes are defined as structural remodelling in AF [4].
However, a more detailed description, based on bioche-
mical reactions that characterize the state of the connective 
tissue structures, also requires more investigations. It is 
known that collagen — the important exchange product of 
the connective tissue — is synthesized from proline (Pro) 
and lysine that undergo hydroxylation and are transformed 
into hydroxyproline (Hpro) and hydroxylysine. Therefore, 
Hpro can be considered as a marker of collagen formation. 
In the polypeptide strands, the small amino acid glycine 
(Gly) occurs at every third position, when Pro and Hpro 
account for 23% of the total residues.
Atrial fibrosis in AF is the result of a complex interaction 
not only of profibrotic signalling pathways. Activation of va-
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signing an informed consent form that was approved by 
our institution’s committee on human investigation. On 
the admission AF patients underwent pharmacological or 
direct current cardioversion. In all patients with persistent 
AF, cardioversion was performed with a transthoracic elec-
trical shock of 200 to 360 J. No patient AF was terminated 
by radiofrequency catheter ablation. All patients were 
successfully cardioverted and remained in sinus rhythm 
at discharge. So, all study participants (in all groups) were 
in sinus rhythm during examination.
Laboratory methods
Plasma levels of total Hcy and Gly were measured after 
cardioversion by the method of high-performance liquid 
chromatography (HPLC Agilent 1100) with the use of Agilent 
ChemStation A10.01 software (HP, US) [7].
Echocardiography
Two-dimensional transthoracic echocardiography was 
performed using Philips IE-33 system (S5-1, 1–5 MHz, 
Philips, USA). The following parameters were obtained: 
left atrial (LA) systolic diameter, left ventricular (LV) end-
-systolic diameter, LV end-diastolic diameter, LV mass and 
LV mass index.
In additional to standard echocardiographic parame-
ters, LA geometry and function were assessed by measu-
rement of LA volume, LA volume index, LV stroke volume, 
LA ejection fraction using bi-plane area-length method as 
reported previously [8].
Statistical analysis
Normally distributed data are presented as mean ± stan-
dard deviation and non-normally distributed data are 
reported as median and interquartile range. For non-
-normal distribution of data, multiple comparisons among 
three groups were conducted by Kruskal-Wallis H test and 
differences between two groups were assessed by Mann-
-Whitney U test for post hoc analysis. Proportional data 
were compared with a chi square test. A one-way ANOVA 
test was used for assessing the statistical significance 
where appropriate. To identify the relationship between 
indicators of an abnormal distribution, the Spearman rank 
correlation coefficient (R) was used, and the Student’s test 
for the normal distribution of the sign. For the assessment 
of significance of differences in the frequency of quality 
indicators the two-sided Fisher’s exact test was used. Ge-
neral Classification Regression Tree Models analyse was 
used to determine how some indicators influence other 
variables, their hierarchy of influence, thereby defining 
its prognostic significance [9]. The differences were con-
sidered statistically significant when p < 0.05 (2-tailed). 
The analysis was performed using Statistica 6.0 software 
package (Statsoft, US). 
Results
There were no significant differences in age, gender, renal 
function, history of coronary artery disease and hyperten-
sion between the study groups (Table 1), but there were 
significant differences in LA-parameters, that characterize 
its structure and function, in group 2 in comparison with 
other patient groups. It indicates more pronounced remo-
delling process in patients with persistent AF (Table 2).
Total plasma Hcy levels were significantly higher in 
patients with paroxysmal AF (9.42 (7.41–11.32) μmol and 
persistent AF 9.59 (7.27–12.4) μmol as compared to the 
control subjects (6.61 [5.8–8.82] μmol/L, p = 0.005 and 
p = 0.001, respectively) (Figure 1).
In the persistent AF group Hcy plasma concentra-
tion was positively correlated with LA systolic diameter 
(R = 0.45, p = 0.03) (Figure 2).
On the next step we used general regression tree model 
classification as a prediction model that can be represented 
as a decision tree. The Gly level > 349 μmol/L was found to 
be associated with a longer AF duration (Figure 3).
In order to analyse the relationship between Gly plasma 
level and AF duration, the all three patient groups (n = 94) 
were divided into two subgroups according to the Gly 
plasma levels (349 μmol/L). It was revealed that its level 
> 349 μmol/L was significantly more often in patients 
Table 1. Characteristics of the studied patient groups
Patients’ characteristics Paroxysmal AF 
(n = 48)
Persistent AF 
(n = 27)
Controls 
(n = 19)
p value
Age, years 56 (50–64) 53 (46–61) 56 (49–61) NS
Male gender, n [%] 37 (77) 22 (81) 12 (63) NS
Hypertension, n [%] 39 (81) 22 (81) 17 (89) NS
Coronary artery disease, n [%] 41 (85) 21 (78) 14 (74) NS
eGFR [ml/min/1.73 m2] 68 ± 13 66 ± 13 72 ± 18 NS
AF — atrial fibrillation; NS — no significant differences between there groups (by Kruskal-Wallis H test); eGFR — estimated glomerular filtration rate
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Figure 1. Plasma concentration of homocysteine (Hcy) in the stu-
died patients
Figure 2. Correlation between homocysteine and left atrial (LA) 
systolic diameter in patients with persistent atrial fibrillation 
(group 2); Hcy — homocysteine
Table 2. Echocardiographic parameters in studied patient groups
Parameters Paroxysmal AF  
(n = 48)
Persistent AF  
(n = 27)
Control  
(n = 19)
p value
Left atrial parameters
Systolic diameter [mm] 38 ± 3* 41 ± 4*# 36 ± 2 0.0015
Stroke volume [ml] 35 ± 10 30 ± 9 35 ± 10 NS
Diastolic volume [ml] 70 ± 16 78 ± 18* 61 ± 18 NS
Systolic volume [ml] 34 ± 14 47 ± 18*# 26 ± 9 0.0008
Systolic volume index [ml/m2] 16 ± 6 24 ± 10*# 13 ± 4 0.0005
Diastolic volume index [ml/m2] 34 ± 7 39 ± 10 31 ± 8 NS
Ejection fraction [%] 52 ± 11 37 ± 11*# 58 ± 7 0.0001
Left ventricular parameters
Mass index [g/m2] 118 ± 25 119 ± 22 105 ± 14 NS
End-diastolic volume [ml] 128 ± 20 131 ± 29 121 ± 26 NS
End-systolic volume [ml] 42 ± 10 52 ± 23* 37 ± 9 NS
Stroke volume [ml] 84 ± 14 79 ± 14 81 ± 17 NS
Ejection fraction [%] 66 ± 5 61 ± 8 *# 68 ± 5 0.0027
*Significant differences compared with control group; #significant differences compared with group 1; AF — atrial fibrillation; NS — no significant differences between there groups (by Kruskal-Wallis H test)
with AF existing for more than four years (46% vs 22%) 
(р = 0.05) (Table 3).
We have also found that the Gly plasma level 
> 309 μmol/L level when total Hcy plasma level was 
> 11.02 μmol/L is associated with a significant AF frequ-
ency increase (Figure 4).
All studied patient groups (n = 94) were divided into 
two subgroups according to Hcy plasma levels (11 μmol/L). 
In the subgroup of patients without AF, Hcy plasma level 
was < 11 μmol/L (0% vs 29%) (р = 0.005), whereas we 
observed different number of AF rhythm disorders per year 
when Hcy plasma concentration was > 11 μmol/L (Table 4).
Discussion
Unfortunately, regulatory roles of amino acids in metabo-
lism have long been ignored. It was tactically assumed, 
without much evidence, that humans could synthesize 
sufficient amounts of all nonessential amino acids, and 
growing evidence from cell culture and animal studies 
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Figure 3. Classification of atrial fibrillation (AF) duration depending 
on the glycine (Gly) plasma level; M — mean value; D — a disper-
sion of the sample; Hpro — hydroxyproline
shows that some of the traditionally classified nonessential 
amino acids can play important roles in multiple signalling 
pathways, thereby regulating gene expression, intracellular 
protein turnover and oxidative defence [10]. There are many 
data indicating Hcy as an independent modifiable risk factor 
for cardiovascular disease [11, 12].
Table 3. The relationship between glycine (Gly) plasma level and atrial fibrillation (AF) duration
 
AF duration
Gly < 349 μmol/L (n = 79) Gly > 349 μmol/L (n = 15) p value
n [%] n [%]
No AF 16 20 3 20 NS
New-onset AF 18 23 2 13 NS
6 months–1 year 10 13 1 7 NS
Up to 4 years 18 23 2 13 NS
More than 4 years 17 22 7 46 0.05*
*Significant difference between two subgroups; NS — no significant differences between there groups (by Kruskal-Wallis H test)
Data based on the Hcy receptor effects leads to 
the important conclusion: one of the leading factors in 
pathobiochemical mechanism of this amino acid action 
is a mitochondrial dysfunction that dysregulates the Ca2+ 
homeostasis.
Figure 4. Atrial fibrillation (AF) frequency classification depending 
on homocysteine (Hcy) and glycine (Gly) plasma levels; M — mean 
value; D — a dispersion of the sample
Table 4. The relationship between homocysteine (Hcy) plasma level and atrial fibrillation (AF) frequency
AF frequency Hcy < 11 μmol/L (n = 65) Hcy > 11 μmol/L (n = 29) p value
n [%] n [%]
No AF 19 29 0 – 0,005*
New on-set AF 13 20 8 28 NS
Up to 2 per year 7 10 7 24 NS
3–9 per year 12 18 5 17 NS
More than 10 per year 14 21 9 31 NS
*Significant difference between two subgroups; NS — no significant differences between there groups (by Kruskal-Wallis H test); NS — nonsignificant
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in the millimolar range. However, when under pathological 
conditions the Gly level in the nervous system grows (stroke, 
head trauma), Hcy neurotoxicity can significantly exceed its 
neuroprotective activity as antagonist of this process. That 
is, the Hcy cyto- and neurotoxicity is the result of excessi-
ve NMDA receptor activation in hyperhomocysteinaemia 
(HHcy) [15]. It could explain why Hcy partially inhibits the 
NMDA-receptors on the glycine binding site and Gly can 
reduce these effects [22].
Conclusions
In our study we investigated the association between Hcy 
and Gly levels, atrial remodelling and the clinical course 
in patients with AF. It can be assumed that in a higher 
level of Hcy (> 11 μmol/L) Gly plasma level may serve as 
a predictor of more pronounced structural and functional 
changes in the atria, but in this case the effect of Gly level 
increasing is likely to be a protective mechanism of HHcy 
in paroxysmal and persistent AF. This fact may explain the 
relationship of elevated Gly levels to a greater AF duration 
and AF frequency. Although such conclusions would be 
expected from theoretical point of view, of course, further 
analyses are needed in this case.
Interest of our study is focused on the fact that in 
patients with paroxysmal and persistent AF with coronary 
artery disease and/or hypertension not only a significant 
Hcy level increase occurs, but the relationship of its level 
> 11 μmol/L to LA-size and AF rhythm disorders per year 
was also revealed.
In conclusion, AF is not a rare condition in either general 
population or patients with hypertension or IHD, and it is 
also associated with increased risk of morbidity and mor-
tality. Therefore, new approaches of identification of atrial 
remodelling that increases the likelihood of AF, especially 
when it seems to be relatively stable, could contribute to 
its prevention, prognosis and treatment.
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Under HHcy, the percentage of contractile cells, the 
maximum speed rate, the maximum rate of relaxation and 
amplitude of Ca2+ transfer in the myocardium is significantly 
reduced [13].
Recently, it was demonstrated that Hcy was able to 
act as an antagonist of the N-methyl-D-aspartate (NMDA) 
receptors on its glutamate binding site. At the same time, 
Gly is the agonist of these receptors on the glycine binding 
site. Hcy can play role as an antagonist at glutamate binding 
site of NMDA-R and as a partial agonist on the Gly binding 
site. Rosenquist et al. [14] showed in their work that the 
NMDA receptor co-agonist Gly provided a highly signifi-
cant level protection against Hcy-induced developmental 
abnormalities.
It has been shown that NMDA-receptors are widely 
represented in organs and various tissues including hu-
man heart [15]. Many studies highlight the role of these 
receptors in the development of cardiovascular pathology. 
In human myocardium they are concentrated in the nerve 
terminals, ganglia, conductive fibres, and cardiomyocytes 
including atrial myocytes [16]. It has been found that high 
levels of Hcy induce heart failure and arrhythmias by acting 
on NMDA-receptors [17, 18].
There are few studies that explored the relationship 
between increased Hcy level and remodelling in AF. So, 
mechanisms of fibrosis and myocardium remodelling are 
partially associated with the Hcy action on NMDA-recep-
tors. Chronic Hcy activation of NMDA receptors induces 
cardiomyocytes hypertrophy and intramitochondrial nitro-
xide stress, which in turn increase the level of cytoplasmic 
Ca2+ and lead to increase in reactive oxygen species 
(ROS) production and apoptosis [17, 19]. As a result, 
mitochondrial MMP-9 increased activity as well as the 
disintegration and translocation of connexin-43 [16, 20] 
reduce the elastin/collagen ratio, increase interstitial 
collagen deposition between myocytes and endothelial 
cells and lead to fibrosis underlying arrhythmias mani-
festations [21].
The association between Hcy and Gly in the nervous tis-
sue cells was shown earlier. It has been revealed that at Gly 
physiologic concentrations toxic Hcy levels to neurons lies 
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Streszczenie
Wstęp. Migotanie przedsionków (AF) wiąże się z kompleksem różnych czynników, które tworzą wiele mechanizmów 
w wyniku zjawiska przebudowy przedsionków. Celem pracy było zbadanie klinicznych zależności między stężeniami 
homocysteiny (Hcy) i glicyny (Gly) we krwi pacjentów z napadowym i przetrwałym AF.
Materiały i metody. Zbadano 94 pacjentów ze współistniejącymi chorobą niedokrwienną serca i/lub nadciśnieniem 
tętniczym bez uszkodzenia mięśnia sercowego — 48 pacjentów z napadowym AF (grupa 1) i 27 chorych z utrwalonym 
AF (grupa 2). Za pomocą echokardiografii oceniano strukturalno-funkcjonalny stan lewego przedsionka. Mierzono także 
stężenia homocysteiny i glicyny w osoczu krwi.
Wyniki. U pacjentów z AF stężenie Hcy we krwi było znacznie wyższe. W grupie 2 zidentyfikowano znaczące korelacje 
między wartościami Hcy i Gly i parametrami echokardiograficznymi lewego przedsionka, charakteryzując jego strukturę 
i funkcję. Stężenie Gly ponad 349 μmol/l było skojarzone z dłuższym czasem występowania AF i znacznie częściej 
dotyczyło pacjentów z AF istniejącym od ponad 4 lat. Stężenie Gly przekraczające 309 μmol/l przy wartości Hcy ponad 
11,02 μmol/l wiązało się ze wzrostem częstotliwości AF. U pacjentów bez AF wartość Hcy znamiennie częściej wynosiła 
poniżej 11 μmol/l (0% v. 29%) (р = 0,005).
Wnioski. Istnieje związek między stężeniami Hcy i Gly, przebudową przedsionka i przebiegiem klinicznym u pacjentów 
z AF. Można założyć, że wyższa wartość Hcy i zwiększenie stężenia Gly mogą być bardziej przydatne w przewidywaniu wy-
raźnych zmian strukturalnych i funkcjonalnych w przedsionku, jednak w takim przypadku służą jako mechanizm ochronny.
Słowa kluczowe: migotanie przedsionków, homocysteiny, glicyna, echokardiografia, lewy przedsionek, strukturalna 
i funkcjonalna przebudowa przedsionków
(Folia Cardiologica 2015; 10, 5: 323–329)
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